Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HIV antibodies and vaccine design.

× No keyword cloud information.

8 in total

1. Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells.

Authors: F Manca; L Walker; A Newell; F Celada; J A Habeshaw; A G Dalgleish
Journal: Clin Exp Immunol Date: 1992-04 Impact factor: 4.330

Review 2. The AIDS virus. What we know and what we can do about it.

Authors: F Wong-Staal
Journal: West J Med Date: 1991-11

3. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.

Authors: D Durali; J Morvan; F Letourneur; D Schmitt; N Guegan; M Dalod; S Saragosti; D Sicard; J P Levy; E Gomard
Journal: J Virol Date: 1998-05 Impact factor: 5.103

4. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.

Authors: E Björling; K Broliden; D Bernardi; G Utter; R Thorstensson; F Chiodi; E Norrby
Journal: Proc Natl Acad Sci U S A Date: 1991-07-15 Impact factor: 11.205

5. Continuous epitopes of the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein and reactivity of human sera to synthetic peptides representing various HIV-1 isolates.

Authors: P Horal; B Svennerholm; S Jeansson; L Rymo; W W Hall; A Vahlne
Journal: J Virol Date: 1991-05 Impact factor: 5.103

6. Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1.

Authors: K E Ugen; J J Goedert; J Boyer; Y Refaeli; I Frank; W V Williams; A Willoughby; S Landesman; H Mendez; A Rubinstein
Journal: J Clin Invest Date: 1992-06 Impact factor: 14.808

7. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.

Authors: B Rovinski; J R Haynes; S X Cao; O James; C Sia; S Zolla-Pazner; T J Matthews; M H Klein
Journal: J Virol Date: 1992-07 Impact factor: 5.103

8. Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.

Authors: R L Willey; M A Martin; K W Peden
Journal: J Virol Date: 1994-02 Impact factor: 5.103

8 in total